InterVenn Biosciences is analyzing glycoproteins to discover new drug targets to treat disease. Glycosylation is the process of attaching sugar molecules to biological material such as proteins, lipids and RNA. It is important for normal cell function but has also been linked with diseases like cancer. InterVenn is building a unique, powerful liquid-biopsy solution to explore the rich diversity of protein glycosylation, the glycoproteome. InterVenn’s platform uses deep learning to automate analysis of biomarkers to decode the glycoproteome and identify new drug targets. InterVenn has built the world’s first glycoprotein liquid-biopsy laboratory test, GLORI, for ovarian cancer diagnostics, with many other products in the pipeline for cancer diagnostics.

<p>InterVenn Biosciences is analyzing glycoproteins to discover new drug targets to treat disease. Glycosylation is the process of attaching sugar molecules to biological material such as proteins, lipids and RNA. It is important for normal cell function but has also been linked with diseases like cancer. InterVenn is building a unique, powerful liquid-biopsy solution to explore the rich diversity of protein glycosylation, the glycoproteome. InterVenn’s platform uses deep learning to automate analysis of biomarkers to decode the glycoproteome and identify new drug targets. InterVenn has built the world’s first glycoprotein liquid-biopsy laboratory test, GLORI, for ovarian cancer diagnostics, with many other products in the pipeline for cancer diagnostics.</p>


InterVenn BioSciences

Founded: 2017
Location: South SF, CA
Employee range: 50 - 200
Funding: $201M C Aug 2021; $34M B Nov 2020; $9.4M Dec 2018

Short description:

Drug notes:

Long description:

Jobs: